Nama's AI scorecard currently rates Agios Pharmaceuticals Sell (3.9 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

When does AGIO report earnings?

Agios Pharmaceuticals's next scheduled report is on Feb 18, 2027. Analysts expect EPS of -$1.14.

What is the AGIO price target?

The median analyst price target from 8 analysts is $43.50, with a range of $32.00 – $72.00.

Is AGIO Shariah compliant?

Nama's AAOIFI-style screen reads Agios Pharmaceuticals as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

Agios Pharmaceuticals (AGIO)

Healthcare · Biotechnology · NASDAQ

Agios Pharmaceuticals (AGIO) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $1.76B and a free-cash-flow yield of -22.7%. Over the most recent reported fiscal year, revenue grew 48.0%. Nama's AI scorecard rates it Sell, 3.9 out of 10. On 12-month momentum it ranks in the lagging band of its market.

AI scorecard

Sell · 3.9/10

Negative, at the mild end of Sell. As of Nov 7, 2026.

Momentum

Lagging · -21.1% over 12 months ex. last

Second-worst fifth of its market on the past year's move.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-53.0%

How far the last close sits under the highest price of the past five years.

Market cap	$1.76B
Trailing P/E	—
Price / book	1.7
Price / sales	17.8
FCF yield	-22.7%
Dividend yield	—
Gross margin	92.0%
Operating margin	-466.8%
Net margin	-418.2%
Revenue growth (YoY)	+48.0%
Revenue growth (3-yr annual)	+56.0%
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	0.6
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

AGIO earnings

Next report: Feb 18, 2027 (Q4 2026, EPS estimate -$1.14). Beat the EPS estimate in 3 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 5, 2026	-$1.09	-$1.23	+11.4%	—
Q2 2026	Jul 30, 2026	-$1.69	-$1.66	-1.8%	$44.74M
Q1 2026	Apr 29, 2026	-$1.69	-$1.79	+5.6%	$20.75M
Q4 2025	Feb 12, 2026	-$1.85	-$1.94	+4.6%	$19.97M

AGIO analyst price target

Median target $43.50 from 8 analysts, ranging $32.00 – $72.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9

Explore live AGIO data on Nama Insights →

Recent Congressional trades

Agios Pharmaceuticals trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
Gilbert Cisneros	House	Buy	$1,001 - $15,000	Sep 10, 2026
Gilbert Cisneros	House	Buy	$1,001 - $15,000	Apr 7, 2026
Gilbert Cisneros	House	Buy	$1,001 - $15,000	Jan 12, 2026
Gilbert Cisneros	House	Buy	$1,001 - $15,000	May 6, 2025
Gilbert Cisneros	House	Buy	$1,001 - $15,000	Feb 11, 2025
Josh Gottheimer	House	Buy	$1,001 - $15,000	Feb 15, 2024

AGIO FAQ

Is AGIO a buy?: Nama's AI scorecard currently rates Agios Pharmaceuticals Sell (3.9 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does AGIO report earnings?: Agios Pharmaceuticals's next scheduled report is on Feb 18, 2027. Analysts expect EPS of -$1.14.
What is the AGIO price target?: The median analyst price target from 8 analysts is $43.50, with a range of $32.00 – $72.00.
Is AGIO Shariah compliant?: Nama's AAOIFI-style screen reads Agios Pharmaceuticals as Not Shariah Compliant. At least one of the three ratios or the industry test failed.